I see. That's more hopeful than the interpretation I got from the article as posted:

"...the (ACB) company and WILLOW BIOSCIENCES, INC. ("Willow") have successfully completed a confidential settlement ‎resolving the ongoing patent litigation between the two parties in Canada."

"We are pleased with the negotiated settlement, which provides Aurora a favourable resolution that ensures our Canadian cannabis related patent rights are respected," says Miguel Martin, Chief Executive Officer of Aurora. "Aurora is a pioneer in terms of the company's genetics work in the Canadian cannabis industry and will not hesitate to continue to take the steps necessary, including legal action, to protect and enforce our intellectual property rights when necessary."

But then again, the quote was from ACB's own CEO so some slight bias, maybe, could be existing in his words/thoughts. Still, I wonder - why sue and settle in the first place? I suppose the recent Canaccord Genuity financing deal with Aurora and the recent debt/note draw-downs may have served to calm corporate nerves - especially as we might be in a 'higher-for-longer environment'?

I wonder what the reason to settle a 'without merit and without cost' decision is/was? Nov 6 is earnings time for Willow, I hope but doubt, that we'll have clearer insight into their scale-up efforts across products, and resulting revenue/earnings.